HC Wainwright Has Bearish Estimate for NAMS FY2025 Earnings

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) – Research analysts at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for NewAmsterdam Pharma in a note issued to investors on Wednesday, November 5th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($1.68) per share for the year, down from their prior estimate of ($1.42). HC Wainwright currently has a “Buy” rating and a $52.00 price target on the stock. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for NewAmsterdam Pharma’s Q4 2025 earnings at ($0.55) EPS and FY2026 earnings at ($1.33) EPS.

A number of other brokerages have also recently issued reports on NAMS. Needham & Company LLC lifted their price objective on NewAmsterdam Pharma from $40.00 to $46.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Citigroup lifted their price target on shares of NewAmsterdam Pharma from $42.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 17th. The Goldman Sachs Group assumed coverage on shares of NewAmsterdam Pharma in a research report on Thursday, July 17th. They issued a “neutral” rating and a $27.00 price target on the stock. Royal Bank Of Canada raised their price objective on shares of NewAmsterdam Pharma from $39.00 to $44.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Wednesday, October 8th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $44.30.

NewAmsterdam Pharma Price Performance

NewAmsterdam Pharma stock opened at $39.89 on Monday. The business has a 50 day simple moving average of $32.03 and a 200 day simple moving average of $24.82. The company has a market capitalization of $4.49 billion, a PE ratio of -19.46 and a beta of 0.05. NewAmsterdam Pharma has a one year low of $14.06 and a one year high of $41.47.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03). The business had revenue of $0.35 million for the quarter, compared to the consensus estimate of $4.54 million. NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%.

Hedge Funds Weigh In On NewAmsterdam Pharma

Large investors have recently made changes to their positions in the company. Alps Advisors Inc. raised its holdings in NewAmsterdam Pharma by 4.4% during the 1st quarter. Alps Advisors Inc. now owns 77,961 shares of the company’s stock worth $1,596,000 after purchasing an additional 3,252 shares during the last quarter. Arizona State Retirement System bought a new position in shares of NewAmsterdam Pharma in the 1st quarter valued at about $215,000. HB Wealth Management LLC grew its position in shares of NewAmsterdam Pharma by 28.9% during the 1st quarter. HB Wealth Management LLC now owns 11,247 shares of the company’s stock worth $230,000 after buying an additional 2,519 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of NewAmsterdam Pharma by 130.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company’s stock worth $123,000 after buying an additional 3,390 shares during the last quarter. Finally, Bryce Point Capital LLC bought a new stake in shares of NewAmsterdam Pharma during the first quarter worth approximately $438,000. Institutional investors and hedge funds own 89.89% of the company’s stock.

Insider Transactions at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 150,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $25.83, for a total value of $3,874,500.00. Following the completion of the sale, the chief accounting officer owned 15,000 shares of the company’s stock, valued at $387,450. This trade represents a 90.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director James N. Topper acquired 1,260 shares of NewAmsterdam Pharma stock in a transaction on Monday, September 8th. The shares were purchased at an average cost of $24.99 per share, for a total transaction of $31,487.40. Following the acquisition, the director owned 3,027,864 shares in the company, valued at approximately $75,666,321.36. This represents a 0.04% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have sold 226,342 shares of company stock worth $5,748,019. Corporate insiders own 20.84% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.